Kodiak Sciences surges 90% after eye drugs match Regeneron's Eylea

Kodiak Sciences stock jumped more than 90% premarket Monday after its drugs Zenkuda and KSI-501 showed non-inferiority to aflibercept, the active ingredient in Regeneron's Eylea, in wet AMD. Shares were on track to open at a four-year high. 285 clean stories shaped this window, with sentiment leaning bullish at 56/100. Also in focus: Lifecore Biomedical to be acquired by Webster Equity Partners for $6.28 per share.